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Background: Phosphoinositide-3 (PI-3) kinase signaling has a pervasive role in cancer.
One of the key effectors of PI-3 kinase signaling is AKT, a kinase that promotes growth and survival in a variety of cancers. Genetically engineered mouse models of prostate cancer have shown that AKT signaling is sufficient to induce prostatic epithelial neoplasia (PIN), but insufficient for progression to adenocarcinoma. This contrasts with the phenotype of mice with prostate-specific deletion of Pten, where excessive PI-3 kinase signaling induces both PIN and locally invasive carcinoma. We reasoned that additional PI-3 kinase effector kinases promote prostate cancer progression via activities that provide biological complementarity to AKT. We focused on the PKN kinase family members, which undergo activation in response to PI-3 kinase signaling, show expression changes in prostate cancer, and contribute to cell motility pathways in cancer cells.
Methods: PKN kinase activity was measured by incorporation of 32 P into protein substrates. Phosphorylation of the turn-motif (TM) in PKN proteins by mTOR was analyzed using the TORC2-specific inhibitor torin and a PKN1 phospho-TM-specific antibody. Amino acid substitutions in the TM of PKN were engineered and assayed for effects on kinase activity. Cell motility-related functions and PKN localization was analyzed by depletion approaches and immunofluorescence microscopy, respectively.
The contribution of PKN proteins to prostate tumorigenesis was characterized in several mouse models that express PKN transgenes. The requirement for PKN activity in prostate cancer initiated by loss of phosphatase and tensin homolog deleted on chromosome 10 (Pten), and the potential redundancy between PKN isoforms, was analyzed by prostate-specific deletion of Pkn1, Pkn2, and Pten.
Results and Conclusions: PKN1 and PKN2 contribute to motility pathways in human prostate cancer cells. PKN1 and PKN2 kinase activity is regulated by TORC2-dependent phosphorylation of the TM, which together with published data indicates that PKN proteins receive multiple PI-3 kinase-dependent inputs. Transgenic expression of active AKT and PKN1 is not sufficient for progression beyond PIN.
Moreover, Pkn1 is not required for tumorigenesis initiated by loss of Pten. Triple knockout of Pten, Pkn1, and Pkn2 in mouse prostate results in squamous cell carcinoma, an uncommon but therapy-resistant form of prostate cancer.
K E Y W O R D S
mouse models, PI-3 kinase, phosphorylation, squamous cell carcinoma 1 | INTRODUCTION PI-3 kinases are a family of lipid-and protein-modifying enzymes that regulate cellular functions including growth, proliferation, survival, and motility. Abnormal signaling by PI-3 kinases is a common feature of a variety of cancers and occurs by multiple mechanisms. The most common mechanism is reduction or loss of PTEN, a tumor suppressor that negatively regulates PI-3 kinase by dephosphorylating the phosphorylated phosphatidyl inositol products. PTEN mutations and deletions occur in approximately 30% of primary human prostate tumors, and about 63% of metastatic tumors. [1] [2] [3] [4] Genetically engineered mouse models have been developed to study how PI-3 kinase and PTEN contribute to cancer initiation and progression. The PTEN knockout is embryonic lethal, 5 but hypomorphic alleles of PTEN and conditional mutants using Cre-lox have been used to formally demonstrate that PTEN functions as a tumor suppressor in multiple murine tissues including the prostate. [6] [7] [8] [9] Conditional loss of Pten in mouse prostate results in PIN by about 6 weeks, and HGPIN by 8-9 weeks, with 100% penetrance. These mice develop focal invasion that progresses to wide spread locally invasive cancer in the majority of animals by 6-12 months. 6, 10 One of the major effectors of PI-3 kinase signaling that is robustly activated upon loss of PTEN is AKT/PKB. AKT activation is PI-3 kinaseactivity sensitive because it contains a pleckstrin homology (PH) domain that binds phosphorylated phosphatidyl inositol generated at the plasma membrane. Once recruited to the plasma membrane, AKT is phosphorylated by 3-phosphoinositide-dependent kinase 1 (PDK1), which also contains a PH domain. Activated AKT contributes to tumorigenesis mostly through enhanced survival mechanisms, but also through increased proliferative and metabolic pathways. 11 A causal role for AKT in prostate cancer was examined by expressing myrisotylated AKT (myr-AKT; denoted active AKT) in mouse prostate. 12, 13 The myrisotylation tag drives AKT association with the plasma membrane resulting in its activation, even in WT cells. It was found that expression of active AKT is sufficient to generate highly penetrant PIN, but progression to adenocarcinoma and metastasis was not observed even after 78 weeks. 10, 12, 13 The fact that expression of activated AKT is not sufficient to 
| Antibodies
The antibodies used in this study included PKN1 (BD Biosciences 
| Recombinant proteins
GST-AR(607-620) and GST-Marcks were expressed in bacterial strain BL21(DE3)pLysS (EMD Millipore, Billerica, MA), and purified on glutathione beads using standard protocols.
| Other reagents
The other reagents included Torin (Thermo Fisher Scientific #424710), 
| Binucleate measurements
These experiments were conducted as previously described. 
| Gene expression analysis
Normalized gene expression data were obtained from the publicly available TCGA Data Portal. Using the PRAD dataset, comparisons between 52 prostate cancer (blue) and adjacent normal tissue (yellow)
were represented via box and whisker plots. The expression values are calculated as "mRNA expression RNA-Seq by ExpectationMaximization (RSEM)," whiskers represent the minimum and maximum datapoints, and significance was determined using a paired t-test. The GSE6919 dataset 24 was downloaded for the following comparisons:
normal (n = 63), prostate tumor (n = 65), and metastasis (n = 25).
Significance was evaluated with an ANOVA combined with Tukey's multiple comparisons test.
| Mice
Mouse embryonic injections were done in the Genetically Engineered , and the experimental animals generated from intercrossing the offspring. All animal procedures were approved by the Animal Care and Use Committee at the University of Virginia, which is fully accredited by the AAALAC.
| Histology, immunofluorescence, and whole mount imaging
Tissues were fixed in formalin, paraffin embedded, and sectioned at 5 microns, and were stained with hematoxylin and eosin (H&E), or prepared for immunostaining as previously described. 10, 26, 27 Images were captured on a Nikon Eclipse NI-U with a DS-QI1 or DS-Ri1 camera and NIS Elements software, and adjusted in Adobe Photoshop.
Antibodies were as follows: rabbit anti-Krt10, chicken anti-Krt5, mouse anti-Krt8, and rabbit anti-Ki-67. Alexafluor 488, 546, and 647 secondary antibodies were from Thermo Fisher Scientific. Whole-mount in situ hybridization was performed on embryos with digoxigenin-labeled riboprobes, as described. 28 β-galactosidase staining was carried out as described 29 .
Whole mount images were captured on a Leica MZ16 stereomicroscope and QImaging 5.0 RTV digital camera.
| RESULTS
The carboxyl terminal region of AGC family members contains elements that are critical for regulating the structure and activity of the catalytic domain. 19 One of the elements that has been studied in detail is the turn motif (TM). In Akt and PKC, and other AGC family members, phosphorylation of the TM promotes stabilization and activity of the kinase through its contact with the amino-terminal small lobe (N-lobe) of the catalytic core. In this setting, the TM helps a second phosphorylated element, the hydrophobic motif (HM), wrap around the N-lobe and dock with the HM pocket. 19 The carboxyl terminal regions of PKN are 40-50% identical to PKC and Akt enzymes, and include sequences that are similar to the TM (see Figure 2A ). To assess whether the sequences resembling the TM in PKN proteins contribute to protein function, we introduced alanine substitutions into the predicted phospho-acceptor sites in the TM sequences of human PKN1 and PKN2. We then analyzed the kinase activity of WT and mutant proteins following expression in mammalian cells. Using Histone H3 as a substrate, PKN1 S916A and PKN2 T958A
showed substantial reductions in kinase activity relative to the WT proteins ( Figure 1A ).
TM phosphorylation in Akt and PKC enzymes is dependent on mTORC2 and occurs during protein translation. 21, 30 We applied the mTOR inhibitor Torin, which inhibits mTORC1 and mTORC2, to cells expressing WT PKN1 and PKN2 to test whether mTOR signaling is important for PKN kinase activity. PKN1 and PKN2 isolated from
Torin-treated cells showed reduced phosphorylation of Histone H3, consistent with mTOR signaling to these kinases ( Figure 1A ). We Histone H3 has been shown to be a PKN1 substrate. 31 We found but not by PKN1 S916A ( Figure 1E ). From these experiments, we conclude the TM makes a critical contribution to PKN kinase activity toward multiple substrates, and that PKN kinase activity can be regulated by mTOR.
Alignment of the TM sequences from human PKCα, PKNs, and AKT1 shows the putative phospho-acceptor site in PKN1 is a serine, while in the other kinases, this position is a threonine (Figure 2A ). To determine if the TM of PKN1 is phosphorylated in cells, we generated an antibody to a peptide containing phospho-Ser916 and used it for probing transfected PKN1. Antibody that was affinity-purified on the phospho-peptide recognized WT PKN1, and it displayed a low level of reactivity towards PKN S916A. Background reactivity was, however, eliminated when a low concentration of non-phosphorylated peptide was included in the antibody incubation ( Figure 2B ). PKN1 S916A was phosphorylated on T774 of the activation loop, indicating TM phosphorylation. 31, 39 We used a PKN1 monoclonal antibody to stain a cohort of normal, primary, and metastatic prostate cancers. We found that PKN1 expression is increased in primary tumors, and undergoes a further increase in metastatic sites ( Figures 5A and 5B ).
TCGA data (RNAseq) revealed that PKN1 expression is increased in prostate cancer (52 normal, 52 cancer), while PKN2 and PKN3 underwent a slight reduction in expression ( Figure 5C ). Akt expression was increased in tumor samples while PKCα was decreased ( Figure   5C ), the latter consistent with a tumor suppressor function. 40 mTOR catalytic subunit expression in this data set is higher in prostate tumors, Moreover, they show that the kinase responsible for TM phosphorylation (mTOR) and PKN activity is increased in tumor versus normal prostate cells ( Figure 5C ).
| Pkn2 is required for embryonic development
To understand the roles of PKN function in vivo, we obtained mouse ES cells with targeted alleles of Pkn1 and Pkn2. These alleles were created by KOMP as knock-out first alleles that can be converted to conditional alleles in which an essential exon is flanked by loxP sites (see Supplemental Figure S2 ). Mice were generated from the two ES cell lines by standard procedures and germ-line transmission of each of the two Pkn alleles verified by PCR. For simplicity, we have termed the original KOMP knock-out first alleles "k," the conditional alleles "f" (for loxP flanked), and the Cre recombined, "r." We first analyzed mice with the k alleles of either Pkn1 or Pkn2 for viability and fertility. As shown in Table 1 , intercrossing Pkn1 +/k heterozygotes generated Pkn1 k/k mice at approximately the expected frequency in either a mixed strain background (C57BL6/N × 129 Sv/J), or in a pure C57BL6/N background. In addition to being viable, Pkn1 k/k mice bred successfully. In contrast to the Pkn1 mutation, mice with homozygous Pkn2 k/k alleles were not recovered at weaning, although Pkn2 +/k heterozygotes appeared to be normal, and were obtained at the expected frequency from Pkn2 +/k heterozygous intercrosses and from Pkn2 +/k by wild-type crosses (Table 1) . We also observed a lack of homozygous Pkn2 mutant animals when Pkn2 +/r mice were intercrossed, suggesting that the Cre recombined allele was also a null. Mice that were doubly heterozygous for both Pkn1 and Pkn2 were viable and appeared grossly normal.
When we intercrossed these double heterozygotes all genotypes were observed at the expected frequency at weaning, except for Pkn2 k/k FIGURE 5 Analysis of PKN isoform expression in human prostate cancer. A, Representative IHC showing PKN1 protein levels in normal, primary tumor, and lymph node metastasis. B, PKN1 and PKN2 expression (using microarray data from reference 47) in normal prostate, primary tumor, and metastases. C, RNA expression (using RNAseq data from TCGA) of PKN1-3 isoforms, PTEN, PKCα, AKT, and select mTOR components. **P < 0.01, ***P < 0.001, ****P < 0.0001
homozygotes, suggesting that there was not a synthetic effect of deleting one Pkn2 allele on top of both Pkn1 alleles, for example (Table   2 ). Analyzing the genotypes for each gene separately from these crosses further emphasized the lack of genetic interaction, at least as far as overall viability is concerned.
In addition to generating a conditional loxP flanked allele by Flpmediated recombination, we created lacZ reporter alleles (termed Pkn1 +/z and Pkn2 +/z ) for both Pkn1 and Pkn2 by first introducing a Cre recombinase (see Supplemental Figure S2 ). At embryonic day 10.5 (E10.5), we observed minimal staining for the lacZ reporter in Pkn1 +/z embryos, whereas by E11.5, staining was evident in neural tissue, somites, limb buds, pharyngeal pouches, and the ventral region of the forebrain ( Figure 6A ). In contrast to Pkn1, Pkn2 expression was evident from E6.5 to E9.5 and Pkn2 appeared to be expressed widely throughout the embryo at all stages examined ( Figure 6A ). To determine when during development Pkn2 null embryos failed, we generated litters of embryos from Pkn2 +/k intercrosses at E7.5-E12.5.
At E7.5-E10.5, Pkn2 k/k homozygous embryos were identified, but all were clearly defective or severely delayed as compared to littermate controls (Table 3) . Representative examples of Pkn2 k/k homozygotes are shown ( Figure 6B ). By E7.5, the formation of the well-defined embryonic layers is delayed. In the Pkn2 null embryos that were observable at E10.5, there was formation of the body axis, and specification of head and other major structures had initiated ( Figure   6B ). However, axial extension was clearly reduced and the embryos have not fully turned. To further examine axis formation, we examined control and Pkn2 null embryos at E7.5 by whole mount in situ hybridization. Expression of the anterior neural marker, Otx2 appeared to be relatively normal in Pkn2 nulls, and Brachyury expression was also observed on the side of the embryo that was morphologically consistent with being the posterior ( Figure 6C ). This suggests that
Pkn2 null embryos specify the anterior-posterior axis and initiate the formation of neural tissue and posterior mesoderm, but fail to fully extend the axis and fail to progress to organogenesis. This is in agreement with a previous report detailing embryonic lethality and mesenchyme defects in Pkn2 null embryos. 42 
| Analysis of Pkn function in prostate tumorigenesis
To explore the potential role of PKN proteins in prostate cancer progression, we took advantage of three genetically engineered mouse models that have been well characterized and recapitulate features of human prostate cancer. 43 Our major focus was PI-3 kinase signaling, since deletions and mutations in PI-3 kinase pathway components are common in prostate cancer. We made use of the Pten model of prostate cancer since conditional deletion of Pten in mouse prostate induces high-grade prostate intraepithelial neoplasia (HGPIN) by 8-9 weeks and locally invasive cancer by 6-12 months. 6, 10, 44 The second model we used is based on a transgenic mouse expressing constitutively active AKT (caAKT), which develops HGPIN but does not become invasive. 10, 12 The third model we used was TRAMP, which expresses Large T and small t antigens and develops HGPIN by 10-12 weeks of age. 45 The overall strategy was to test whether transgenic expression of PKN1 would enhance tumorigenic phenotypes, and whether PKN deletion would reduce tumorigenesis in these models.
Published studies have indicated that PKN expression is increased in human prostate cancer. 38, 39 To test if altered Pkn1 expression could contribute to prostate tumor formation or progression in a mouse model, we first generated two lines of transgenic mice in which human PKN1 was expressed from a modified probasin (Pb) promoter that drives prostate epithelium-specific expression. 23 In one line, this promoter was linked to full length wild-type PKN1 (Tg-PKN1), and in the other, we expressed an amino-terminally truncated version of Figure S3) PKN1 that is constitutively active (Tg-PKN1ΔN) ( Figure 7A ). Mice expressing either of these transgenes were normal and fertile, and even after 1 year of age, we observed no effects of transgene expression in the prostate ( Figure 7B ; Supplemental Figure S3A ). Duct morphology appeared indistinguishable from that seen in wild-type mice and we detected no signs of dysplasia in the transgenic animals.
Expression of AKT1 from the probasin promoter has been shown to cause hyperplasia and low-grade PIN (prostate intra-epithelial neoplasia) that progresses to invasive cancer rarely, and generally only after more than 1 year of age. In our previous analyses, we observed phenotypes in ventral prostate of ∼85% of Tg-AKT1 mice, consistent with earlier reports. 10 When we compared the phenotype of Tg-AKT1 mice to those with both the Tg-AKT1 and one or other PKN1 transgene, we did not observe any advancement of the AKT1-mediated PIN phenotype to invasive cancer even by more than 1 year of age ( Figure 7C ; Supplemental Figure S3B and Table 4 Table 4 ).
Conditional prostate-specific deletion of the Pten tumor suppressor has been one of the more widely used mouse models for prostate cancer. 43 Homozygous Pten deletion results in the development of PIN in all mice by around 6-8 weeks of age; the phenotype progresses rapidly to HGPIN and eventually to invasive cancer. (Table 4) . Similarly, comparing the phenotypes in ventral prostate between Pten null and Pten null tumors lacking both Pkn1 and Pkn2 did not reveal any consistent differences ( Figure 8C ; Supplemental Figure S4C ; and Table 4 ). However, in mice that had reached 45-60 weeks of age, we noticed the occurrence of extensive squamous differentiation, primarily in the anterior and dorsolateral lobes in three of four Pten r/r ;Pkn1 r/r ;Pkn2 r/r mice at ∼53 weeks ( Figure 8D ; Supplemental Figure S4D ; and 44 We observed strong expression of Krt10 and Krt5 in the tumors with squamous differentiation, that was distinct from regions of luminal cells marked by Krt8 expression ( Figure 9A ). Since showing widespread expression during early development. In agreement with previous work, 52 it appears that Pkn2 null embryos are developmentally delayed by E7.5, but do establish proximo-distal and anterior-posterior axes, suggesting that embryonic patterning is relatively normal. However, axis extension and embryo turning are defective, consistent with cell motility defects as seen in vitro with Pkn depletion. 48 We used a panel of genetically engineered mouse models to rigorously examine the contributions of Pkn1 to prostate tumorigenesis. We explored our hypothesis that Pkn1 cooperates with Akt during PI-3 kinase-dependent prostate tumorigenesis using two strategies. seems probable that activation of these two kinases is insufficient for disease progression presumably because additional PI-3 kinaseregulated components are in play in the setting of Pten loss. We also introduced the Pkn1 transgenes into the TRAMP mouse. We observed no obvious effect on tumorigenesis, though it is possible that the strain background or cohort size limited our ability to detect subtle PKN transgene effect in this setting. We then considered the possibility that Pkn1 function and its biological effects in these models could be restrained by expression of Pten. Expression of Pkn1 in the background of Pten loss, however, had no obvious impact on turmorigenesis. We generated Pten r/r ;Pkn1 r/r ;Pkn2 r/r mice and examined the prostates for effects on tumorigenesis initiated by loss of Pten.
FIGURE 9 Squamous differentiation in
Deletion of Pkn1 and Pkn2 did not alter the HGPIN or locally invasive phenotype caused simply by the loss of Pten. However, in older mice prostate cancer, the etiology is not defined. The prognosis for these patients is very poor for this therapy-resistant cancer, with survival times ranging from 1 to 13 months. 53, 54 Our data suggest that signaling through PKN might act as a restraint to squamous differentiation.
| CONCLUSIONS
The kinase activity of PKN1 and PKN2 is regulated by TM phosphorylation mediated directly, or indirectly, by the TORC2 complex. PKN proteins contribute important cell motility functions in multiple cancer cell types, including prostate cancer. Pkn1 and Pkn2 function may be important for helping specify the differentiation state of prostate cancers that have lost the tumor suppressor Pten.
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